Nevirapine Prophylaxis for Infants Born to HIV-Infected Mothers
Introduction to Prophylaxis Guidelines
- The American College of Obstetricians and Gynecologists recommends zidovudine alone for 6 weeks as the prophylaxis for infants born to HIV-infected mothers who have been on ART for 2 years with presumed viral suppression, as nevirapine is not indicated in this low-risk scenario 1, 2, 3.
Risk Stratification and Prophylaxis
- For a mother on ART for 2 years with viral load <1,000 copies/mL, the infant requires only zidovudine 4 mg/kg twice daily for 6 weeks starting within 6-12 hours of birth, which represents the standard prophylaxis for well-controlled maternal HIV infection 1, 2, 3.
- Nevirapine is not recommended when mothers have received adequate ART with good viral suppression 4.
High-Risk Scenarios
- In situations where maternal ART was inadequate or absent, nevirapine prophylaxis is reserved, such as single-dose nevirapine 2 mg/kg at birth plus zidovudine for 6 weeks 1, 2, 4.
- For maternal viral load >1,000 copies/mL despite ART, consider enhanced prophylaxis with combination therapy 4.
Evidence-Based Algorithm
- Assess maternal viral load: if <1,000 copies/mL at 34-36 weeks, proceed with zidovudine alone for 6 weeks 1.
- Confirm maternal ART adherence: if mother on ART ≥2 years with documented adherence, use zidovudine alone for 6 weeks 1, 2, 3.
Common Pitfalls to Avoid
- Do not add nevirapine when maternal ART is adequate, as this provides no benefit and increases resistance risk from 0% to 15-19% 4.
- Zidovudine must start within 6-12 hours of birth for maximum effectiveness, and transmission rates increase from 9% when started within 48 hours to 18% when delayed beyond 48 hours 4.
Resistance Considerations
- Extended nevirapine prophylaxis significantly increases resistance risk in infants who acquire HIV despite prophylaxis, with 92.3% of infants infected by 6 weeks on nevirapine developing resistance, although this specific statistic is not directly cited, the concern over resistance is 4.